Atopic prurigo nodularis responds to intravenous immunoglobulins

British Journal of Dermatology

Volumn 166, Issue 2, 2012, Pages 461-462

  Feldmeyer, L ^a   Werner, S ^b   Kamarashev, J ^a   French, L E ^a   Hofbauer, G F L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Private Practice ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CANDESARTAN; CYCLOSPORIN A; DAPSONE; DOXYCYCLINE; ETRETIN; IMMUNOGLOBULIN; INTRATEC; METHOTREXATE; STEROID; THALIDOMIDE; UNCLASSIFIED DRUG;

ACANTHOSIS; ADULT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARM; ATOPIC DERMATITIS; ATOPIC PRURIGO NODULARIS; CASE REPORT; DERMATITIS; DERMIS; DISEASE SEVERITY; DRUG TREATMENT FAILURE; ECZEMA; EOSINOPHIL; EPIDERMIS; ERYTHEMA; EXOCYTOSIS; FEMALE; HEADACHE; HUMAN; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; KERATINIZATION; LETTER; LICHENOID; LONG TERM CARE; NAUSEA; PAPULE; PARAKERATOSIS; PHOTOTHERAPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; PUVA; SENSITIZATION; SKIN BIOPSY; SKIN DEFECT; SKIN DISEASE; SKIN FIBROSIS; SKIN NODULE; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; VISUAL ANALOG SCALE;

CHRONIC DISEASE; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; PRURIGO; TREATMENT OUTCOME;

EID: 84856227658     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10587.x     Document Type: Letter

References (9)

1. Accioly-Filho LW, Nogueira A, Ramos-e-Silva M,. Prurigo nodularis of Hyde: an update. J Eur Acad Dermatol Venereol 2000; 14: 75-82.
2. Tanaka M, Aiba S, Matsumura N, et al. Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic. Dermatology 1995; 190: 269-76.
3. Jolles S,. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin Exp Dermatol 2002; 21: 3-7.
4. Bemanian MH, Movahedi M, Farhoudi A, et al. High dose intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis. Iran J Allergy Asthma Immunol 2005; 4: 139-43.
5. Paul C, Lahfa M, Bachelez H, et al. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002; 147: 518-22.
6. Ishii N, Hashimoto T, Zillikens D, Ludwig RJ,. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol 2010; 38: 186-95.
7. Prins C, Gelfand EW, French LE,. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 2007; 87: 206-18.
8. Bonilla FA,. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008; 122: 1238-9.
9. Feldmeyer L, Benden C, Haile SR, et al. Not all intravenous immunoglobulin preparations are equally well tolerated. Acta Derm Venereol 2010; 90: 494-7.